Interleukin-1 blockade in refractory giant cell arteritis

This publication has 13 references indexed in Scilit:

• Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
  Arthritis Care & Research, 2012
• Efficacy of tocilizumab in refractory giant cell arteritis
  Joint Bone Spine, 2012
• Therapeutic approach to giant cell arteritis
  Joint Bone Spine, 2012
• A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects
  Annals of the Rheumatic Diseases, 2008
• Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta‐analysis
  Arthritis & Rheumatism, 2007
• Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis
  Annals of Internal Medicine, 2007
• Elastic-Vessel Arteritis in Interleukin-1 Receptor Antagonist–Deficient Mice Involves Effector Th1 Cells and Requires Interleukin-1 Receptor
  Circulation, 2005
• Tissue production of pro-inflammatory cytokines (IL-1 , TNF and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis
  Rheumatology, 2003
• Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes
  Arthritis Care & Research, 2003
• Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double‐blind, placebo‐controlled trial
  Arthritis & Rheumatism, 2002